New 'Living Drug' trial offers hope for Tough-to-Treat blood cancer
NCT ID NCT07447726
Summary
This early-stage study is testing a new type of CAR-T cell therapy for adults with large B-cell lymphoma that has come back or hasn't responded to other treatments. Doctors will give a single infusion of these specially modified immune cells to 3 participants to first check if it's safe and to see early signs of whether it can shrink tumors. The main goal is to understand the treatment's side effects and how well patients respond.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA (LBCL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.